AU2007300663A1 - Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions - Google Patents

Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions Download PDF

Info

Publication number
AU2007300663A1
AU2007300663A1 AU2007300663A AU2007300663A AU2007300663A1 AU 2007300663 A1 AU2007300663 A1 AU 2007300663A1 AU 2007300663 A AU2007300663 A AU 2007300663A AU 2007300663 A AU2007300663 A AU 2007300663A AU 2007300663 A1 AU2007300663 A1 AU 2007300663A1
Authority
AU
Australia
Prior art keywords
epitope
polynucleotide
hla
epitopes
htl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2007300663A
Other languages
English (en)
Inventor
Jeffery L. Alexander
Pamuk A. Bisel
Mark J. Newman
Scott F. Southwood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmexa Inc
Original Assignee
Pharmexa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmexa Inc filed Critical Pharmexa Inc
Publication of AU2007300663A1 publication Critical patent/AU2007300663A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AU2007300663A 2006-07-21 2007-07-23 Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions Abandoned AU2007300663A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83211206P 2006-07-21 2006-07-21
US60/832,112 2006-07-21
PCT/US2007/016529 WO2008039267A2 (fr) 2006-07-21 2007-07-23 Induction de réponses immunes cellulaires au virus de la grippe grâce à des compositions de peptides et d'acides nucléiques

Publications (1)

Publication Number Publication Date
AU2007300663A1 true AU2007300663A1 (en) 2008-04-03

Family

ID=39230737

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007300663A Abandoned AU2007300663A1 (en) 2006-07-21 2007-07-23 Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions

Country Status (4)

Country Link
EP (1) EP2069376A4 (fr)
AU (1) AU2007300663A1 (fr)
CA (1) CA2658559A1 (fr)
WO (1) WO2008039267A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103333224A (zh) * 2013-05-10 2013-10-02 中国农业科学院哈尔滨兽医研究所 禽流感病毒ns1蛋白b细胞抗原表位多肽及其应用

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101660363B1 (ko) 2007-06-25 2016-09-28 더 어드미니스트레이터즈 오브 더 튜래인 어듀케이셔널 훤드 인플루엔자를 억제하는 조성물 및 방법
CA2695399C (fr) * 2007-08-02 2017-10-17 Biondvax Pharmaceuticals Ltd. Vaccins contre la grippe a multiples epitopes multimeres
EP2296688A2 (fr) * 2007-10-26 2011-03-23 Glykos Finland Oy Vaccin peptidique contre le virus de la grippe
FI20080333A0 (fi) * 2008-05-02 2008-05-02 Glykos Finland Oy Influenssaviruksen nukleiinihappoja ja peptidejä
CA2744348C (fr) * 2008-11-19 2017-02-14 Laboratorio Avi-Mex, S.A. De C.V. Vaccin recombinant a vecteur viral inactive
US8282938B2 (en) 2008-11-28 2012-10-09 National Institute Of Infectious Diseases Immunogenic compositions comprising liposomes and an influenza PB2 CTL epitope obtained from the highly pathogenic H5N1 strain
WO2010086294A2 (fr) 2009-01-28 2010-08-05 Epimmune Inc. Polypeptides de liaison de pan-dr et leurs utilisations
US20100310591A1 (en) * 2009-01-28 2010-12-09 Robert Humphreys Ii-KEY HYBRID PEPTIDES THAT MODULATE THE IMMUNE RESPONSE TO INFLUENZA
CN101792745B (zh) * 2009-02-04 2014-09-17 中国科学院生物物理研究所 流感病毒聚合酶亚基pa氨基端多肽的表达纯化及pa氨基端多肽的晶体结构
CN101565455B (zh) * 2009-05-25 2012-03-14 中国科学院微生物研究所 禽流感h5n1病毒的ctl表位多肽及其应用
US8926982B2 (en) * 2009-06-01 2015-01-06 Xuguang Li Reagents and methods for detecting influenza virus proteins
BR112012008060A2 (pt) 2009-07-31 2016-11-22 Paxvax Inc vetores baseados em adenovírus
CA2775720A1 (fr) * 2009-09-30 2011-04-07 Saint Louis University Peptides declenchant des reponses hetero sous-typiques des lymphocytes t contre la grippe
CN102153621B (zh) * 2010-02-12 2014-07-02 广东省疾病预防控制中心 新型甲型h1n1流感na蛋白b细胞表位及其应用
US9149025B2 (en) 2010-02-19 2015-10-06 Universite De Liege Polynucleotide for use in treatment of influenza A virus induced diseases, encoding modified Mx protein, said modified Mx protein, and a transgenic animal expressing gene encoding modified Mx protein
WO2011138032A2 (fr) * 2010-05-05 2011-11-10 Artemev, Timur Vaccins antigrippaux universels et leurs procédés de production
CN105061534A (zh) 2010-09-22 2015-11-18 艾丽奥斯生物制药有限公司 取代的核苷酸类似物
CN103517713A (zh) 2011-02-22 2014-01-15 彼昂德瓦克斯医药有限公司 在改善的季节性和大流行性流感疫苗中的多聚体多表位多肽
WO2013059403A1 (fr) * 2011-10-19 2013-04-25 Immunotope, Inc. Immunogènes induisant des lymphocytes t cytotoxiques pour prévenir, traiter, et diagnostiquer l'infection par le virus de l'influenza
AU2012358804B2 (en) 2011-12-22 2018-04-19 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
WO2013093514A2 (fr) * 2011-12-23 2013-06-27 Retroscreen Virology Ltd Vaccins - peptides
US8916538B2 (en) 2012-03-21 2014-12-23 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
NZ630805A (en) 2012-03-22 2016-01-29 Alios Biopharma Inc Pharmaceutical combinations comprising a thionucleotide analog
US20140193484A1 (en) * 2013-01-10 2014-07-10 Sylvie Carine Bertholet Girardin Influenza virus immunogenic compositions and uses thereof
WO2015186721A1 (fr) * 2014-06-03 2015-12-10 国立研究開発法人農業・食品産業技術総合研究機構 Anticorps ou fragment d'anticorps comprenant une région variable de celui-ci, polypeptide antigénique et utilisations de ceux-ci
CN111148528A (zh) 2016-12-28 2020-05-12 英福瓦克思公司 流感疫苗
CN106589105B (zh) * 2017-01-23 2020-09-15 中国医科大学 Hla-a2限制性ecm1特异性的ctl表位肽及其应用
EP3679056A1 (fr) * 2017-09-08 2020-07-15 The University of Melbourne Procédés et compositions pour la prévention d'une infection grippale
CN111315407B (zh) * 2018-09-11 2023-05-02 上海市公共卫生临床中心 一种广谱抗流感疫苗免疫原及其应用
JP2023530135A (ja) * 2020-06-19 2023-07-13 インターベット インターナショナル ベー． フェー． 特定のウイルス系統の抗原をエンコードする核酸構築物を含むブタインフルエンザａウイルスワクチン
WO2021255225A1 (fr) * 2020-06-19 2021-12-23 Intervet International B.V. Vaccin contre le virus de la grippe porcine comprenant une construction d'acide nucléique comprenant des première, deuxième et troisième séquences d'acide nucléique codant pour des antigènes de neuraminidase distincts du virus
WO2022032274A1 (fr) * 2020-08-02 2022-02-10 Richard Ascione Compositions de vaccins contre les virus de la grippe et méthodes d'utilisation
TW202219062A (zh) * 2020-08-25 2022-05-16 美商建南德克公司 用於特性化ｍｈｃｉ肽結合的測定及試劑
CN116410271B (zh) * 2023-03-13 2024-07-19 华南农业大学 H5n1亚型aiv mhc b1限制性t细胞表位肽及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7572620B2 (en) * 2005-01-11 2009-08-11 Wisconsin Alumni Research Foundation H3 equine influenza A virus

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103333224A (zh) * 2013-05-10 2013-10-02 中国农业科学院哈尔滨兽医研究所 禽流感病毒ns1蛋白b细胞抗原表位多肽及其应用

Also Published As

Publication number Publication date
WO2008039267A2 (fr) 2008-04-03
EP2069376A2 (fr) 2009-06-17
WO2008039267A3 (fr) 2008-12-31
CA2658559A1 (fr) 2008-04-03
EP2069376A4 (fr) 2013-10-16

Similar Documents

Publication Publication Date Title
AU2007300663A1 (en) Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions
DK2023952T3 (en) Induction of immune responses to influenza virus using polypeptide and nucleic acid compositions
KR101983989B1 (ko) 인플루엔자 바이러스 백신 및 이의 용도
KR101736897B1 (ko) 인플루엔자 항원 수송 벡터 및 구조물
JP2023524054A (ja) ベータコロナウイルスの予防と治療
CN112469661A (zh) 具有新结构组分的纳米粒疫苗
Sharma et al. A self-adjuvanted, modular, antigenic VLP for rapid response to influenza virus variability
CN105473604A (zh) 融合前rsv f蛋白和其用途
AU2007213562A2 (en) Peptide sequences and compositions
JP2010535026A (ja) 多量体マルチエピトープインフルエンザワクチン
Reginald et al. Development of peptide vaccines in dengue
US9963490B2 (en) Influenza nucleoprotein vaccines
Frangione-Beebe et al. Enhanced immunogenicity of a conformational epitope of human T-lymphotropic virus type 1 using a novel chimeric peptide
McMurry et al. A call to cellular & humoral arms: enlisting cognate T cell help to develop broad-spectrum vaccines against influenza A
US9896484B2 (en) Influenza virus recombinant proteins
WO2020041311A1 (fr) Vecteurs pour induire des réponses immunitaires à des épitopes non dominants dans la protéine hémagglutinine (ha)
Sia et al. Engineered nanoparticle applications for recombinant influenza vaccines
JP2023534840A (ja) Ｍ２／ｂｍ２欠失インフルエンザベクターを使用したワクチン
RU2358981C2 (ru) Универсальная вакцина против вируса гриппа птиц
Naskalska et al. Influenza recombinant vaccine: matrix protein M1 on the platform of the adenovirus dodecahedron
JP2022553258A (ja) インフルエンザウイルスワクチン及びその使用
Skarlas et al. Influenza virus H5N1 hemagglutinin (HA) T‐cell epitope conjugates: design, synthesis and immunogenicity
Park et al. Development of Self-Assembled Protein Nanocage Spatially Functionalized with HA Stalk as a Broadly Cross-Reactive Influenza Vaccine Platform
WO2020086927A1 (fr) Peptides pour induire des réponses hétérosubtypiques de lymphocytes t de la grippe
EA046906B1 (ru) Вакцины против вируса гриппа и пути их применения

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application